Tetra Bio-Pharma Plans Phase 2 Trial of Vaporized PPP001 Cannabis Product for Fibromyalgia Pain

Tetra Bio-Pharma Plans Phase 2 Trial of Vaporized PPP001 Cannabis Product for Fibromyalgia Pain
Tetra Bio-Pharma is planning a Phase 2 clinical trial to test its PPP001 vaporized medical cannabis product as a treatment for pain in patients with fibromyalgia. This follows the positive results of a Phase 1 trial in healthy volunteers, which demonstrated that the investigational product is generally safe and well-tolerated, the company announced. The company successfully completed the trial, which explored the safety of PPP001, as well as its stability and distribution in the body. It was conducted in the United States and Canada, and enrolled 12 healthy volunteers who received increasing doses of PPP001 for four days followed by a single dose of vaporized PPP001. Interim analysis of the clinical data has provided a deeper understanding of the process of administering cannabinoids to patients. The information may help health regulators decide the best strategies in the future for patients with chronic pain. “We are thrilled with the results of this trial which was completed both on time and on budget,” Guy Chamberland, PhD, CEO and chief scientific officer of Tetra Bio-Pharma, said in a press release. “We look forward to investigating this vaped version of PPP001 in patients who suffer from the debilitating pain of fibromyalgia.” The positive effects of cannabis and cannabis-derived substances to alleviate pain and other conditions have been pre
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *